California biotech entrepreneur and former magician Serhat Gumrukcu has been found guilty of orchestrating the 2018 murder of his business rival Gregory Davis, who had threatened to expose Gumrukcu's fraudulent dealings. He faces sentencing in November. SFGATE reports: Seven years ago, Turkish national Serhat Gumrukcu, 42, of Los Angeles, was negotiating a multimillion-dollar biotech merger built off his work on a supposed HIV cure. The deal was put in jeopardy by a former business partner named Gregory Davis, 49, who had threatened to bring legal action against Gumrukcu for fraudulent activities relating to a previous failed oil commodities deal, the U.S. Attorney's Office said in a news release last week. Gumrukcu, a magician-turned-scientist who admitted to buying his medical degree from a Russian university, lived in a Hollywood mansion and partied with Oscar winners and movie producers, according to VTDigger. He stood to make millions from the merger of his biotech company Enochian BioSciences. [...] In 2017, upon learning that Davis, a father of six from Danville, Vermont, could potentially spoil his fortune-making deal, Gumrukcu set in motion a hit on the former business partner. The murder-for-hire plot involved four men in total, prosecutors said. Gumrukcu had a close friend from Las Vegas, Berk Eratay, approach a third man, Aron Ethridge to find a hit man to kill Davis. The shooter, 37-year-old Montana man Jerry Banks, arrived at Davis' home on Jan. 6, 2018, in a vehicle fitted with flashing red and blue lights and posed as a deputy U.S. marshal. After abducting Davis, Banks shot him dead in the vehicle and left the body partially buried in a snowbank nearby. Investigators soon narrowed in on Gumrukcu after discovering emails between him and Davis revealing tensions over the failed oil deal. Gumrukcu was interviewed twice by the FBI and made false statements on both occasions, federal prosecutors said. Further inspection of cellphone data, bank information and messages identified the four men involved in the kidnapping and killing of Davis.

Read more of this story at Slashdot.

"A small number of researchers are making real progress trying to create computers out of living cells," reports the BBC: Among those leading the way are a group of scientists in Switzerland, who I went to meet. One day, they hope we could see data centres full of "living" servers which replicate aspects of how artificial intelligence (AI) learns — and could use a fraction of the energy of current methods. That is the vision of Dr Fred Jordan, co-founder of the FinalSpark lab I visited. We are all used to the ideas of hardware and software in the computers we currently use. The somewhat eyebrow-raising term Dr Jordan and others in the field use to refer to what they are creating is "wetware". In simple terms, it involves creating neurons which are developed into clusters called organoids, which in turn can be attached to electrodes — at which point the process of trying to use them like mini-computers can begin... For FinalSpark, the process begins with stem cells derived from human skin cells, which they buy from a clinic in Japan. The actual donors are anonymous... In the lab, FinalSpark's cellular biologist Dr Flora Brozzi handed me a dish containing several small white orbs. Each little sphere is essentially a tiny, lab-grown mini-brain, made out of living stem cells which have been cultured to become clusters of neurons and supporting cells — these are the "organoids"... After undergoing a process which can last several months, the organoids are ready to be attached to an electrode and then prompted to respond to simple keyboard commands... Electrical stimulations are important first steps towards the team's bigger goal of triggering learning in the biocomputer's neurons so they can eventually adapt to perform tasks... FinalSpark are not the only scientists working in the biocomputing space. Australian firm Cortical Labs announced in 2022 that it had managed to get artificial neurons to play the early computer game Pong. In the US, researchers at Johns Hopkins University are also building "mini-brains" to study how they process information — but in the context of drug development for neurological conditions like Alzheimer's and autism. Thanks to long-time Slashdot reader fjo3 for sharing the news.

Read more of this story at Slashdot.

"Researchers have modified a standard glue gun to 3D print a bone-like material directly onto fractures," reports LiveScience, "paving the way for its use in operating rooms." The device, which has so far been tested in rabbits, would be particularly useful for fixing irregularly shaped fractures during surgery, the researchers say. "To my knowledge, there are virtually no previous examples of applying the technology directly as a bone substitute," study co-author Jung Seung Lee, a biomedical engineer at Sungkyunkwan University in South Korea, told Live Science in an email. "This makes the approach quite unique and sets it apart from conventional methods...." "Further studies in larger animal models are needed before the technology can be used on humans," the article points out. Thanks to long-time Slashdot reader fahrbot-bot for sharing the article.

Read more of this story at Slashdot.

Many Apple Watches will soon be able to alert users about possible high blood pressure, reports Reuters — culminating six years of research and development: Apple used AI to sort through the data from 100,000 people enrolled in a heart and movement study it originally launched in 2019 to see whether it could find features in the signal data from the watch's main heart-related sensor that it could then match up with traditional blood pressure measurements, said Sumbul Ahmad Desai [Apple's vice president of health]. After multiple layers of machine learning, Apple came up with an algorithm that it then validated with a specific study of 2,000 participants. Apple's privacy measures mean that "one of the ironies here is we don't get a lot of data" outside of the context of large-scale studies, Desai said. But data from those studies "gives us a sense of, scientifically, what are some other signals that are worth pulling the thread on ... those studies are incredibly powerful." The feature, which received approval from the U.S. Food and Drug Administration, does not measure blood pressure directly, but notifies users that they may have high blood pressure and encourages them to use a cuff to measure it and talk to a doctor. Apple plans to roll out the feature to more than 150 countries, which Ami Bhatt, chief innovation officer of the American College of Cardiology, said could help people discover high blood pressure early and reduce related conditions such as heart attacks, strokes and kidney disease. Bhatt, who said her views are her own and do not represent those of the college, said Apple appears to have been careful to avoid false positives that might alarm users. But she said the iPhone maker should emphasize that the new feature is no substitute for traditional measurements and professional diagnosis. The article notes that the feature will be available in Apple Watch Series 11 models that go on sale on Friday, as well as models back to the Apple Watch Series 9.

Read more of this story at Slashdot.

Struggling small biotech firms are pivoting into cryptocurrencies, rebranding as "crypto treasuries" or stockpiling digital assets like Ether and Litecoin as a last-ditch effort to boost share prices amid stalled funding and weak drug pipelines. Bloomberg reports: Shares of 180 Life Sciences Corp., now doing business as ETHZilla, tripled after the Peter Thiel-backed company said it had accumulated Ether tokens worth over $350 million. Less than two weeks later, the stock's gains have been erased. In July, Sonnet BioTherapeutics Holdings soared 243% in one volatile session on plans to transform into a public crypto treasury while MEI Pharma Inc. initially doubled on plans to sell shares to fund a Litecoin treasury. Such about-faces are a tried-and-true formula for small firms when funds are low and shares are under pressure. For drugmakers it can be a sudden shift to chase after trendy new treatment targets, still other companies rebrand with buzzwords like artificial intelligence to juice returns. Now some biotech executives are using digital coins to pump new life into flagging shares. So far in 2025, at least 10 biotechs have announced a pivot into digital assets. The announcements frequently spark frenzied, but short-lived, spikes in shares. "If they're low on ideas, if they can't find relevance in drug development, they're going to try to justify their existence as management in another way," according to Mike Taylor, lead portfolio manager of the Simplify Health Care ETF. "You have a handful of companies trying to reinvent themselves into some other tangent. And, most, if not all won't work out."

Read more of this story at Slashdot.

"For a few dozen people in the world, the downside of living with a rare immune condition comes with a surprising superpower — the ability to fight off all viruses..." notes an announcement from Columbia University. "At first, the condition only seemed to increase vulnerability to some bacterial infections. But as more patients were identified, its unexpected antiviral benefits became apparent." Columbia immunologist Dusan Bogunovic discovered the individuals' antiviral powers about 15 years ago, soon after he identified the genetic mutation that causes the condition... Bogunovic, a professor of pediatric immunology at Columbia University's Vagelos College of Physicians and Surgeons, soon learned that everyone with the mutation, which causes a deficiency in an immune regulator called ISG15, has mild, but persistent systemic inflammation... "In the back of my mind, I kept thinking that if we could produce this type of light immune activation in other people, we could protect them from just about any virus," Bogunovic says. Today, Bogunovic is closing in on a therapeutic strategy that could provide that broad-spectrum protection against viruses and become an important weapon in next pandemic. In his latest study, published August 13 in Science Translational Medicine, Bogunovic and his team report that an experimental therapy they've developed temporarily gives recipients (hamsters and mice, so far) the same antiviral superpower as people with ISG15 deficiency. When administered prophylactically into the animals' lungs via a nasal drip, the therapy prevented viral replication of influenza and SARS-CoV-2 viruses and lessened disease severity. In cell culture, "we have yet to find a virus that can break through the therapy's defenses," Bogunovic says... Bogunovic's therapeutic turns on production of 10 proteins that are primarily responsible for the broad antiviral protection. The current design resembles COVID mRNA vaccines but with a twist: Ten mRNAs encoding the 10 proteins are packaged inside a lipid nanoparticle. Once the nanoparticles are absorbed by the recipient's cells, the cells generate the ten host proteins to produce the antiviral protection. "We only generate a small amount of these ten proteins, for a very short time, and that leads to much less inflammation than what we see in ISG15-deficient individuals," Bogunovic says. "But that inflammation is enough to prevent antiviral diseases...." "We believe the technology will work even if we don't know the identity of the virus," Bogunovic says. Importantly, the antiviral protection provided by the technology will not prevent people from developing their own immunological memory to the virus for longer-term protection. "Our findings reinforce the power of research driven by curiosity without preconceived notions," Bogunovic says in the announcement. "We were not looking for an antiviral when we began studying our rare patients, but the studies have inspired the potential development of a universal antiviral for everyone." More coverage from ScienceAlert.

Read more of this story at Slashdot.